现有证据表明端粒酶激活是肿瘤发生的关键步骤。端粒酶逆转录酶 (TERT) 由人类 TERT 基因编码，对于端粒酶的表达至关重要。 TERT rs10069690 (C > T) 变异被确定与癌症风险相关，然而，结果不一致。因此，我们进行了全面的荟萃分析，旨在阐明该变异与癌症易感性之间的关联。我们在 PubMed、EMbase、MEDLINE 和 Cochrane Library 中进行了截至 2024 年 4 月 30 日的文献检索。总体而言，有 55 项研究涉及 334,196 名患者本研究中包括癌症患者和 741,187 名对照者。所有统计分析均采用STATA软件（版本11.0）进行。汇总结果显示，等位基因模型下rs10069690与癌症风险增加之间存在显着相关性（OR = 1.10，95% CI：1.07-1.13，P < 0.001），尤其是在欧洲和亚洲人群中。按癌症类型分层时，该变异与乳腺癌（OR = 1.11，95% CI：1.07-1.15，P < 0.001）、卵巢癌（OR = 1.14，95% CI：1.10-1.19，P）风险升高相关。 <0.001），肺癌（OR = 1.20，95％CI：1.07-1.35，p = 0.003），甲状腺癌（OR = 1.23，95％CI：1.15-1.32，p <0.001），胃癌（OR = 1.31 ，95% CI：1.19-1.45，P < 0.001）和肾细胞癌（OR = 1.29，95% CI：1.07-1.55，P = 0.007），而肝细胞癌、前列腺癌和胰腺癌的风险降低。我们的结果还表明，该变异与实体癌显着相关（OR = 1.11，95% CI：1.07-1.14，P< 0.001），但与血液肿瘤无关。这项系统荟萃分析表明，TERT rs10069690 变异是一种癌症的危险因素。然而，这种变异的影响可能因不同类型的癌症和不同种族人群而异。© 2024。作者。

Existing evidence suggests telomerase activation is a crucial step in tumorigenesis. The telomerase reverse transcriptase (TERT), encoded by the human TERT gene, is critical for telomerase expression. The TERT rs10069690 (C > T) variant was identified to be associated with the risk of cancer, however, there have been inconsistent results. Therefore, we performed a comprehensive meta-analysis aiming to clarify the association between this variant and cancer susceptibility.We conducted literature search in PubMed, EMbase, MEDLINE and Cochrane Library up to April 30, 2024. Overall, there are 55 studies involving 334,196 patients with cancer and 741,187 controls included in the present study. All statistical analyses were performed by STATA software (version 11.0).The pooled results showed a significant association between rs10069690 and an increased risk of cancer under allele model (OR = 1.10, 95% CI: 1.07-1.13, P < 0.001), especially in European and Asian populations. When stratified by cancer types, this variant was associated with elevated risk of breast cancer (OR = 1.11, 95% CI: 1.07-1.15, P < 0.001), ovarian cancer (OR = 1.14, 95% CI: 1.10-1.19, P < 0.001), lung cancer (OR = 1.20, 95% CI: 1.07-1.35, P = 0.003), thyroid cancer (OR = 1.23, 95% CI: 1.15-1.32, P < 0.001), gastric cancer (OR = 1.31, 95% CI: 1.19-1.45, P < 0.001), and renal cell carcinoma (OR = 1.29, 95% CI: 1.07-1.55, P = 0.007), while decreased risk was found for hepatocellular carcinoma, prostate cancer and pancreatic cancer. Our results also indicated that this variant was significantly associated with solid cancer (OR = 1.11, 95% CI: 1.07-1.14, P < 0.001), but not with hematological tumor.This systematic meta-analysis demonstrated that the TERT rs10069690 variant was a risk factor for cancer. However, the effects of this variant may vary in different types of cancer and differ across ethnic populations.© 2024. The Author(s).